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Aggregated misfolded proteins are hallmarks of most neurodegenerative diseases. In a chronic disease state, including patho-
logic situations of oxidative stress, these proteins are sequestered into inclusions. Accumulation of aggregated proteins can be
prevented by chaperones, or by targeting their degradation to the UPS. If the accumulation of these proteins exceeds their
degradation, they may impair the function of the proteasome. Alternatively, the function of the proteasome may be preserved
by directing aggregated proteins to the autophagy-lysosome pathway for degradation. Sequestosome 1/p62 has recently been
shown to interact with polyubiquitinated proteins through its UBA domain and may direct proteins to either the UPS or au-
tophagosome. P62 is present in neuronal inclusions of individuals with Alzheimer’s disease and other neurodegenerative dis-
eases. Herein, we review p62’s role in signaling, aggregation, and inclusion formation, and speciﬁcally as a possible contributor
to Alzheimer’s disease. The use of p62 as a potential target for the development of therapeutics and as a disease biomarker is also
discussed.
Copyright © 2006 Marie W. Wooten et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Many neurodegenerative diseases such as polyglutamine re-
peat diseases, Lewy bodies in Parkinson disease, Alzheimer’s
disease, tauopathies, and others share abnormal accumula-
tion of ubiquitinated proteins into aggregates and inclusions
as a hallmark feature of the disease pathology. The molec-
ular basis for the accumulation of these inclusions remains
poorly deﬁned; however the aberrant accumulation of ag-
gregated proteins and disturbances in protein degradation
suggest a common underlying mechanism. These inclusions
shareamyloid-likestructureandseveralbiochemicalfeatures
suchas:ubiquitin,aggregatedproteins,proteasomesubunits,
chaperones,andotherproteinsthatbecometrappedthrough
their association with aggregated proteins. Here we review
the role of aggregates, protein turnover, and the ubiquitin
proteasome system (UPS), and focus on the role of a re-
cently discovered proteasomal shuttling protein, sequesto-
some 1/p62, and its role in neurodegeneration. We also dis-
cuss the potential of employing p62 as a biomarker for neu-
rodegenerative disease and as a potential target for therapeu-
tic development.
MISFOLDING AND THE UPS PATHWAY
In normal cells, large amounts of newly synthesized pro-
teins are defective “oﬀ-pathway” products. Even with abun-
dant molecular chaperones, nearly 30% of nascent pro-
teins are misfolded due to mutations or ineﬃcient assem-
bly [1]. To correct these mistakes, misfolded proteins can
either be degraded via the ubiquitin proteasome pathway
(UPS) shortly after their synthesis or they may form ag-
gregates of high molecular weight oligomers [2]. The ul-
timate fate of misfolded proteins depends on kinetic par-
titioning between these two competitive pathways [3]. Be-
cause aggregates are more stable than the improperly folded
protein, to degrade misfolded substrates eﬀectively the pro-
teasome must win the competition for the misfolded sub-
strates before they have an opportunity to aggregate. Un-
der normal conditions, accumulated proteins are removed
promptly before any damage can be caused to the cell.
However under certain situations in nerve cells, accumu-
lated proteins are prone to form inclusion bodies which
are the hallmarks of several neurodegenerative diseases
[4, 5]. Increasingly it is becoming apparent that these2 Journal of Biomedicine and Biotechnology
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Figure 1: The pathway of ubiquitin-linked degradation of proteins
and the 26S proteasome (see [84]).
inclusions/aggresomes may be the sites for sequestration
of aggregated proteins. Herein, we will attempt to clarify
the function and toxicity of protein aggregates and inclu-
sions.
The UPS is responsible for the degradation of proteins
and it serves as a cellular quality control system that tags
misfolded proteins with ubiquitin for degradation by the
26S proteasome. Protein degradation via UPS involves two
steps: (1) covalent attachment of polyubiquitin chains to tar-
get proteins, and (2) degradation of the tagged proteins by
26S proteasome complex with release of free and reusable
ubiquitin (Figure 1). Ubiquitin is a protein that forms dif-
ferent chains with itself [6, 7] and serves as a signal through
covalent attachment to other proteins. Three enzymes are
involved in ubiquitination of substrates, eventually result-
ing in the formation of a bond between the C-terminus of
ubiquitin (Gly76) and the ε- a m i n og r o u po fas u b s t r a t el y -
sine residue. Ubiquitin-activating enzyme (E1) forms a thiol
ester with the carboxyl group of Gly76, activating the C-
terminus of ubiquitin. The activated ubiquitin molecule is
carried by ubiquitin-conjugating enzyme (E2) and trans-
ferredtothesubstratelysineresiduebyubiquitin-ligases(E3)
(Figure 2)[ 8]. Additional ubiquitin molecules can be added
to form polyubiquitin chains. The terminal carboxyl of each
ubiquitin is linked to the ε-amino group of a lysine residue
of an adjacent ubiquitin in the chain. Ubiquitin can form
chains in vivo at all seven lysine residues (K6, K11, K27, K33,
K29, K48, K63) (Figure 3)[ 9]. Polyubiquitin chains linked
through K48 are a primary signal for protein degradation
[8]. By comparison, K63-linked chains are involved in DNA
repair, ribosome function, mitochondrial DNA inheritance,
the stress response and targeting of proteins for endocyto-
sis [8]. However, it should be noted that a model substrate
tagged with K63-linked tetra-ubiquitin could eﬀectively sig-
nal substrate degradation [10]. A chain of at least four ubiq-
uitin moieties attached to a target protein are required for
substraterecognitionandsubsequentdegradationbythe26S
proteasome [11].
Theubiquitinconjugationcascadecontainsalargefamily
of E2s and an even larger set of E3s. For example, in budding
yeast there is one E1, eleven E2s, and more than twenty E3s
[7]. The large number of E3 enzymes may reﬂect the extraor-
dinarydiversityoftheubiquitinatedsubstratesineukaryotes.
All E3 enzymes belong to three protein families: homologous
to E6AP carboxy terminus (HECT), really interesting new
gene (RING), and UFD2 homology (U-box) proteins. Those
E3s share a common E2-binding domain and a substrate-
interacting domain. One remarkable feature of the ubiquitin
conjugation pathway is the modulation of target protein se-
lection.Thesubstratespeciﬁcitydependsmainlyontheiden-
tity of E3 [7]. On the other hand, biochemical studies have
shown that the identity of E2 can inﬂuence the recognition
of speciﬁc structures of a polymeric ubiquitin modiﬁcation
[12], indicating that the speciﬁcity of the E2/E3 interaction
may determine the ﬁnal selection of the target substrate.
The 26S proteasome is a multimeric protease complex
that plays a central role in protein degradation through both
ubiquitin-dependent and ubiquitin-independent mecha-
nisms. The 26S proteasome complex consists of a 20S core
particle which is proteolytically active, and one or two
19S regulatory caps which are responsible for recognition,
unfolding, deubiquitination, and translocation of substrate
proteins into the lumen of the core particle (Figure 4)[ 13].
The 20S proteolytic core consists of four stacked rings
with two outer α-rings embracing two central β-rings. The
outer rings are each composed of seven diﬀerent alpha sub-
units and the inner rings of seven diﬀerent beta subunits
(Figure 5). The overall structure of the 20S core resembles
a barrel with dimensions of 15nm in length and 11nm in di-
ameter. A central proteolytic chamber is formed by two face-
to-faceβ-ringsandisseparatedby3nmwideβ-annuli.Three
subunits β1, β2, and β5 form the catalytic site. β-subunits
gain proteolytic activity by autolytic processing of the N-
terminal propeptides and the exposure of a critical threonine
residue. Access to the chamber requires reorganization of
the N-terminal H0 helices of the α-subunits which normally
form a seal by interacting with side chains. The N-terminus
of the α3-subunit plays a critical role in the seal formation.
Addition of the 19S cap can induce channel opening, and the
19S ATPase, Rpt2, plays a key role in this process.
Another component of the 26S proteasome, known as
the 19S regulator, which is composed of 17 or 18 subunits,
is responsible for recognition, unfolding, deubiquitination,
and translocation of substrate proteins into the lumen of the
core particle, where the substrate is degraded [13]. In high
salt concentrations, the 19S regulator breaks down into two
subcomplexes; the lid and the base. The base consists of 6
ATPases (Rpt1 to Rpt6) that share a high level of similarityMarie W. Wooten et al 3
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Figure 2: A schematic representation of substrate ubiquitination (see [85]).
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Figure 3: (a) Ubiquitin can be added as a single molecule at one or more sites. Alternatively, the branched chains of polyubiquitin may be
formed. (b) Space-ﬁlled model of ubiquitin indicating the seven lysine residues (see [86]).
to one another. The ATPases form a six-membered ring that
interact directly with the α-ring of the 20S proteasome. Pro-
tein substrates need to pass through the center of this ring
in order to enter the catalytic chamber of 20S proteasome.
In addition, the ATPase ring is involved in the antichaperon
activity required to unfold the protein substrates. The base
also includes non-ATPase subunits, such as Rpn10 (S5a),
which contains an ubiquitin interacting motif (UIM). The
lid subcomplex consists of eight non-ATPase subunits, where
Rpn11 plays a key role in the recycling of ubiquitin by cleav-
ing the ubiquitin chain from the protein substrate.
In addition to the standard proteasomes, cells are able to
produce immunoproteasomes as a transient response to cy-
tokines IFN-γ or TNF-α [14]. IFN-γ induces biosynthesis of
proteasome maturation protein (POMP) and proteasomal
β5i subunit low molecular weight protein 7 (LMP7), accel-
erating the assembly of the immunoproteasome in which
threecatalyticsubunitsarereplacedbyhomologoussubunits
(β1i, β2i, β5i) [15]. The immunoproteasome may partici-
pate in generating antigenic peptides displayed on MHC-
class I molecules [16], but are not limited to this function.
Recent observations reveal that in familial amyotrophic lat-
eral sclerosis (fALS) patients, impaired degradation of mu-
tant SOD1 is associated with a decrease in the constitu-
tive proteasomes and an increase in the immunoprotea-
some level, resulting in selective motor neuron degenera-
tion [17]. In Huntington’s disease (HD), high levels of im-
munoproteasome subunits (LMP2 and LMP7) have also
been observed, and are associated with neurodegeneration,
indicating that immunoproteasomes may play a yet to be4 Journal of Biomedicine and Biotechnology
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deﬁned role in the pathogenesis of neurodegenerative dis-
eases [18].
TARGETING POLYUBIQUITINATED
PROTEINS FOR TURNOVER
Polyubiquitin chains are a signal that targets proteins for
degradation by the proteasome complex. Recognition of
polyubiquitinated proteins by the 26S proteasome plays a
critical role in protein degradation. Presentation of a polyu-
biquitinated substrate to the 26S proteasome takes place
through ubiquitin-interacting proteins, such as S5a, Dsk2,
Rad23, and p62 [19, 20]( Figure 6). Ubiquitin-interacting
proteins involved in ubiquitination/deubiquitination gener-
ally have ubiquitin-association (UBA) domains that can di-
rectly bind to ubiquitin (Figure 7). Previous studies have
shown that most UBA domains bind the polyubiquitin
chains rather than the monoubiquitin ones. Some UBA do-
mains even discriminate further binding K63-linked polyu-
biquitinchainsratherthanK48-linkedchains[21].However,
the interaction between ubiquitin and the UBA domain is a
low-aﬃnity interaction. NMR chemical shift mapping shows
that ubiquitin speciﬁcally, but weakly, binds to a conserved
hydrophobic epitope on the UBA domain, while the UBA
domains can bind to the hydrophobic patch on the surface
oftheﬁve-strandedβ-sheetofubiquitinwithdiﬀerentorien-
tations [22]. The weak interaction may enable rapid assem-
bly and disassembly between polyubiquitin and the shuttling
protein. UBA-containing proteins might contribute to the
regulated capture and transient stabilization of proteins that
are otherwise constitutively degraded [23]. Recent ﬁndings
have shownthatafunctionalUBAdomain is requiredforthe
localization of these shuttling proteins into aggregates [24],
suggesting a common mechanism of ubiquitin-mediated se-
questration of essential ubiquitin-binding proteins into ag-
gregates.
In addition to the UBA domains that bind the polyu-
biquitin chains, shuttling proteins commonly contain a
ubiquitin-like domain (UbL) that binds the proteasome [20,
25, 26]. These proteins are able to shuttle the polyubiquiti-
nated substrates to the 26S proteasome for degradation [27].
Ataxin-3, a proteasome-associated factor, has been shown
to interact with the shuttling protein Rad23 to mediate the
degradation of ubiquitinated substrates, suggesting an im-
portantroleforshuttlingproteinsintheUPS[28].Sinceeach
type of polyubiquitin chain forms a diﬀerent conformation
[29], and each UBA domain may recognize speciﬁc types
of polyubiquitin chains, shuttling the protein may present
chain-speciﬁc polyubiquitinated substrates to the protea-
somefordegradation.Arecentstudyofthepolyubiquitinin-
teraction properties of thirty UBA domains reveals that these
domains can be classiﬁed into four groups [30]: those with
linkage speciﬁc characteristics, those which bind diﬀerent
chains, those which are nondiscriminatory, and those which
do not bind ubiquitin. Moreover, it is possible that non-UBA
sequences may modulate interaction properties in the UBA
domain [30].
PROTEIN AGGREGATES AND NEURODEGENERATION
Protein turnover is dependant on a functional UPS. Fail-
ure to remove the polyubiquitinated proteins may lead to
the accumulation of aggregated proteins [31]. The capacity
of the ubiquitin proteasome pathway can be exceeded either
by overexpression of substrates or by a decrease in protea-
some activity. In cultured cells, proteasomal inhibitors can
causetheaggregationofanoverexpressingdisease-associated
protein [32], indicating that dysfunction of the proteasome
might be a factor that initiates the formation of inclusions.
A recent study has shown that a wide-range of nondisease-
associated proteins is found in inclusions when cells were
treated with proteasomal inhibitors. These proteins include
ubiquitinated or nitrated α-tubulin, SOD-1, α-synuclein,
and 68K neuroﬁlaments [33]. Transient expression of two
unrelated aggregation-prone proteins caused nearly com-
plete inhibition of the UPS, indicating that protein ag-
gregation can directly impair the UPS function [34]. A
positive-feedback mechanism has been proposed to explain
the turnover point of protein aggregation. Impaired protea-
some function may result in an increase in protein aggre-
gates, which leads to a further decline of proteasome activ-
ity. It is important to note that UPS impairment is not the
result of steady-state sequestration of the UPS components,
or simple substrate competition [35]. Direct physical inter-
action between proteasome and aggregates is not required
for UPS impairment, indicating that protein aggregates may
inﬂuence the activity of the proteasome in a currently un-
known manner.
Aggregated proteins may sequester to form inclusions
also referred to as an aggresome, where molecular chaper-
ones, proteasome subunits, ubiquitin, and intermediate ﬁl-
ament (IF) proteins colocalize [3]. The formation of aggre-
somes occurs at the microtubule organizing center (MTOC)
and is considered to be a process distinct from the protein
aggregation[36,37].Theformationofcytoplasmicinclusion
bodies requires active transport of misfolded proteins along
microtubules, with redistribution of the IF protein to form a
cage surrounding the core of aggregated, ubiquitinated pro-
tein [31]. Protein misfolding can be prevented or even re-
versed by chaperones. If chaperone activity fails, then the
proteins must be degraded before aggregation takes place.Marie W. Wooten et al 5
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Thus, aggresomes may serve as sites to sequester polyubiq-
uitinated/misfolded proteins. In this regard, the UPS func-
tionsasasensortocontroldegradationofmisfoldedproteins
that tend to aggregate through exposure of hydrophobic se-
quences[31].Shouldexcessiveamountsofproteinaggregates
accumulate, they may negatively impair the function of the
UPS [34, 35]. Thus, it is critical to sequester aggregated pro-
teins so as to preserve the UPS function.
Recent evidence has shown that early protein aggregates
may be toxic to neuronal cells. Soluble dimers and trimers,
and protoﬁbrils or ﬁbrils of amyloid beta (Aβ)p e p t i d ea r e
cytotoxic [38]. On the other hand, although the early pre-
ﬁbrillar disease-associated protein aggregates are harmful
to cells, the mature ﬁbrils are relatively harmless [39]. In
addition, a previous study reveals that UPS impairment is
independent of inclusion body formation [35]. Altogether,
these observations suggest that the inclusions/aggresome
pathway are likely to be cytoprotective by recruiting mis-
folded proteins eﬀectively isolating them within the cell. In
further support of this mechanism, it has been reported that
inclusion body formation predicts improved survival and
leads to decreased levels for the highly aggregating protein
huntingtin [40].
Theaccumulationofproteinaggregatesandformationof
inclusion bodies are associated with many age-related neu-
rodegenerative diseases, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD), Huntington’s disease, and others,
suggesting that there are direct links between protein aggre-
gates and the resulting pathology [4]( Figure 8). The accu-
mulation of ubiquitin conjugates may reﬂect the failed at-
tempt of the UPS to remove damaged proteins [41]. An im-
portant component linked to aberrations in UPS and to the
pathogenesis of Parkinson’s disease is Parkin, an E3 ubiqui-
tin ligase [42]. A previous report reveals that Parkin can as-
sociate with Rpn10 (S5a), a subunit of the 26S proteasome,
indicating that Parkin may transfer ubiquitin conjugates for
proteasomal degradation [43]. Defects in Parkin may result
in the accumulation of its substrates, such as α-synuclein,
and contribute to the pathogenesis of PD.
There is a strong evidence demonstrating that protea-
some inhibition by pharmacological treatment enhances in-
clusion formation in cellular models. However, there is less
support for the notion that aggregates directly inhibit the
proteasome in any disease state. More studies are needed in
animal models to critically evaluate the role of protein aggre-
gates and inclusions on proteasome function.
SEQUESTOSOME 1/P62, TRAFFICKING, AND
INCLUSION FORMATION
Other aggregate-prone proteins participate in neurodegen-
erative diseases such as Alzheimer’s disease (AD) (Figure 8).
There are two types of protein deposits in AD: extracellular
amyloid plaques rich in Aβ peptides, and intracellular6 Journal of Biomedicine and Biotechnology
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neuroﬁbrillary tangles containing hyperphosphorylated
polyubiquitinated tau [44]. Previous study in our lab has
shown that p62 can shuttle K63-polyubiquitinated tau for
proteasomal degradation. Disturbing tau traﬃcking may
result in the accumulation of insoluble/aggregated tau in the
brain, contributing to AD [45]. Aβ peptides are produced by
proteolytic cleavage of the amyloid precursor peptide (APP).
In solution, Aβ peptides may undergo self-assembly leading
to the transient appearance of soluble protoﬁbrils and
eventually to insoluble ﬁbrils [46]. Recent proteomic study
of amyloid plaques recovered from AD brain revealed that
a total of 488 proteins coisolated with plaques. Moreover,
26 proteins were enriched in plaques by comparison with
surrounding non-plaque tissues, including proteins involved
in cell adhesion, cytoskeleton and membrane traﬃcking,
chaperones, kinase/phosphatase, and regulators [47].
Sequestosome 1/p62 is a highly conserved protein that
was initially identiﬁed as a phosphotyrosine-independent
ligand of the src homology 2 (SH2) domain of p56lck [12].
Sequestosome 1/p62 contains a ubiquitin-associated (UBA)
domain at its C-terminus (Figure 9), which can selectively
bind K63-polyubiquitinated proteins [20]. The ability of p62Marie W. Wooten et al 7
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to interact selectively with K63-polyubiquitinated proteins
[20] supports the idea that sequences in the holoprotein may
modulate the UBA interaction properties [30]. The UBA
domain of the human p62 protein forms a compact three-
helix bundle. A Pro392 → Leu substitution mutation can
modify the UBA domain by extending the N terminus of he-
lix 1. This modiﬁcation aﬀects interaction of p62’s UBA do-
main with polyubiquitin chain binding, and may contribute
to Paget’s disease of bone [49]. In addition, recent studies re-
veal that p62 protein lacking a UBA domain fails to form ag-
gregates in HEK cells with impaired survival responses. This
indicates that the UBA domain is critical for sequestering
polyubiquitinated proteins [20], which is in keeping with a
roleforsequestrationofpolyubiquitinatedproteinsasanun-
derlying contributor to inclusion formation [24].
Sequestosome 1/p62 also contains a PB1 domain that
binds aPKC, a ZZ ﬁnger, a binding site for the RING ﬁn-
ger protein TRAF6, and two PEST sequences (Figure 9)[ 48].
With multiple protein-protein interaction motifs, p62 is also
considered a scaﬀold [48], and has been extensively studied
in the context of neurotrophin signaling. The N-terminus of
p62proteincandirectlyinteractwiththeproteasomesubunit
component [20], and the localization of protein substrates to
the proteasome is suﬃcient for degradation [50]. Thus, p62
is also viewed as a shuttling protein, playing an important
role in sequestering polyubiquitinated substrates, interacting
with ubiquitinated substrates through its UBA domain and
the proteasome through its N-terminus [51]. In support of
a shuttling role for p62, we have observed that p62 is nec-
essary for both tau and TrkA interaction with the protea-
some [45, 51]. In addition, we ﬁnd that p62 −\− mice pos-
sess AD-like neurodegeneration [Babu and Wooten, unpub-
lished]. Likewise depletion of nerve growth factor (NGF) re-
sults in AD-like neurodegeneration in anti-NGF transgenic
mice [52]. Interestingly, decreased membrane TrkA expres-
sion has been correlated with decline in performance on
the mini mental state exam and may serve as a marker for
late stage AD [53]. The correlation between the phenotype
of the p62 −/− mice and the anti-NGF mice is suggestive
of an overlap in pathways wherein p62 and NGF function.
Further studies will be needed to sort out the exact mecha-
nism whereby p62 regulates the traﬃcking of TrkA.
The N-terminal PB1 domain of p62 is involved in p62
self-interaction, and in interaction with other proteins that
possess a PB1 domain [54]. However, the PB1 domain can
assume a ubiquitin fold and this may be the basis of the
N-terminus of p62 interacting with the proteasomal subunit
S5a [20]. Overexpression of p62 results in large inclusions,
while depletion of p62 retards protein degradation and leads
to accumulation of nondegraded aggregated polyubiquiti-
nated proteins [20]. We have shown that cells which possess
p62inclusionspossessenhancedsurvivalcharacteristics[55].
This ﬁnding supports the growing idea that inclusions are
sites for sequestration of misfolded proteins that are being
triaged for degradation. In this regard, p62 has been local-
izedtoubiquitincontaininginclusionsinAlzheimer’sdisease
containing tau [56]. Since p62 has been shown to be neces-
sary for tau interaction with the proteasome [45], it is possi-
blethatpolyubiquitinatedtaumayaccumulateintheabsence
of p62. Studies are underway to examine p62’s role in tau
traﬃcking. Culture of mouse embryo ﬁbroblasts from wild
type or p62 −/− mice challenged with either chloroquine, a
lysosomal inhibitor, or MG132, a proteasomal inhibitor, re-
vealsthatp62isnecessaryforinclusionformationunderpro-
teasome impaired conditions (Figure 10). Altogether, these
ﬁndings suggest that p62 plays a key role in traﬃcking, reg-
ulation of aggregation and inclusion body formation. It is
likely that p62 containing inclusions observed in AD and
other neurodegenerative diseases contain proteins destined
for degradation. In the absence of p62 these proteins would
be expected to accumulate in their misfolded polyubiquiti-
nated state and contribute to neurodegeneration.
The genomic structure of p62 reveals the presence of
a CpG island and multiple binding sites for SP-1, AP-1
NF-κB, and Ets-1 family transcription factors in the pro-
moter region, suggesting that p62 transcription may be reg-
ulated by these factors [57]. In this regard either inhibi-
tion of the proteasome or increases in free radicals have
been shown to induce p62 expression [58]. Moreover, in-
hibition of p62 transcription blocked proteasomal-induced
sequestration of ubiquitinated proteins, and the enlarge-
ment of inclusions [59]. These studies support the idea
that p62 is intimately involved in the formation of inclu-
sions and in the protection of cells from the toxicity of
misfolded proteins by enhancing inclusion formation [20,
55]. Thus, inclusions may arise as a protective mechanism
against stress conditions. Indeed, we ﬁnd that cells overex-
pressing p62 possess large inclusions and enhanced survival
[20, 55].
Sequestosome 1/p62 may also act as a scaﬀold of TRAF6
[48, 60]. In this regard, p62 could serve as a site for TRAF6
dependent K63-polyubiquitination of target substrates and
in the activation of transcription factor NF-κB. Interestingly,
TRAF6 colocalizes into inclusions along with p62 [20]. A
recent study in our lab has shown that the p62-UBA do-
main is required for TRAF6 polyubiquitination, suggesting
that p62 may carry ubiquitin chains needed for the activa-
tion/autoubiquitination of TRAF6 [60]. When the interac-
tion between p62 and TRAF6 was disrupted by competitive
inhibitory peptide, the formation of p62/TRAF6 inclusions
in cultured cells was suppressed and survival diminished [20,
45]. Therefore, p62 regulates activation of NF-κB through8 Journal of Biomedicine and Biotechnology
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Figure 10: Mouse embryo ﬁbroblasts (MEF) from wild type (WT) or p62 −/− mice were treated with chloroquine or MG132 as shown.
After 24 hours, the cells were ﬁxed and stained with primary antibody to ubiquitin and secondary antibody to Texas Red.
recognition of TRAF6-catalyzed polyubiquitin chains and/or
recruitment of TRAF6 to a microenvironment to enhance
protein ubiquitination.
In addition, p62 can form a ternary complex with aPKC
and PAR-4 (a stress induced transcript) [61]. Interaction
of aPKC with PAR-4 blocks its activity; however, p62 can
antagonize PAR-4-induced aPKC inhibition [61]. Moreover,
recent studies have shown that p62 can modulate associa-
tion of Akt with aPKC [62]. Thus, p62 through interaction
with aPKC likely regulates cell survival and death signaling
through aPKC/PAR-4 [61] and aPKC/Akt [62]. Also, PAR-4
has recently been shown to interact with BACE and regulates
the production of Aβ peptide [63].
Therefore, it would not be surprising to observe that in
situations where PAR-4 is induced during oxidative stress
or injury that low expression of p62 might compromise the
neuron and contribute to development of neurogeneration.
Excessive accumulation of misfolded proteins is known to
provoke oxidative stress and induce PAR-4 expression [61].
Moreover, oxidatively modiﬁed proteins are resistant to pro-
teolysisandmayfurtherenhanceaccumulationofaggregated
proteins [64]. We hypothesize that decline in expression of
p62 could serve as a biomarker for those individuals at risk
for developing neurodegenerative disease. In this model, ag-
ing and oxidative stress along with diminished expression of
p62 would deﬁne a threshold where proteins fail to properly
fold or triage for degradation, survival signaling is impaired,
and the neurodegenerative disease phenotype is manifested.
Interestingly mutation in valsolin-containing protein (VCP),
a ubiquitin binding protein involved in UPS traﬃcking, has
been linked to frontotemporal dementia [65]. We speculate
that p62, as well as other ubiquitin binding proteins, may
be candidate-genes for detailed genetic analysis. The goal
herewouldbetoexaminepotentialpolymorphismsthatmay
serve as risk determinants for neurodegenerative disease. In
keeping with this hypothesis, recent genetic analysis of the
ubiquilin 1 gene (UBQLN1) revealed that certain genetic
variantsincreasetheriskofAD[66].SimilartoVCPandp62,
UBQLN1 encodes a protein that serves as a shuttling protein
to deliver polyubiquitinated proteins to the proteasome for
degradation.
RELATIONSHIP OF MALLORY BODIES TO
INCLUSION BODIES
Mallory bodies (MB) are a disease-associated type of aggre-
somes/inclusion consisting of excessive accumulation of ker-
atin and are characteristic of alcoholic steatohepatitis (ASH)
and nonalcoholic steatophepatitis (NASH). These inclu-
sion share abnormal liver morphology observed in Wilson’sMarie W. Wooten et al 9
disease (WD), Indian childhood cirrhosis (ICC), and idio-
pathic copper toxicosis (ICT) [67]. ICC and ICT individuals
developcopperinducedcirrhosisoftheliverbyconsumption
of contaminated water or milk [67]. WD mutations in
A T P 7 Bl e a dt oa b n o r m a lc o p p e ra c c u m u l a t i o ni nv a ri o u st i s -
sues, particularly the liver [67]. Copper-mediated oxidative
stressmayalsoplayapathogenicroleinchronicneurodegen-
erative diseases such as Alzheimer’s disease. Sequestosome
1/p62 is an integral component of MB [68] and of the Mal-
lory like-inclusions found in WD, ICC, and ICT, suggest-
ing that p62 may play a role in their formation. The for-
mation of MBs can be induced by prolonged alcohol intox-
ication and chronic metabolic disturbances [68]. Impaired
protein degradation has been implicated as an underlying
factor in alcoholic liver disease similar to its role in chronic
neurodegenerative disorders [67–69]. Moreover, removal of
p62 blocked the formation of MBs, whereas over expression
enhanced their formation [69]. MBs contain high molecu-
lar weight polyubiquitin conjugates as well [69], which sug-
gest that these are sites for sequestration of polyubiquiti-
nated/misfolded proteins. As previously mentioned, p62 ex-
pression is transcriptionally regulated, in particular to agents
of oxidative stress [58, 59]. Oxidative stresses causing alter-
ations in mitochondria are well recognized as contributors
to Alzheimer’s disease [70, 71]. Oxidatively damaged mito-
chondria are removed by a process of autophagocytosis [72],
a process that declines with age. Altogether, these ﬁndings
stronglysuggestthatp62playsaroleintheformationofMBs
which may have similarity to inclusion bodies observed in
neurodegenerative disease.
AUTOPHAGY AS A ROUTE TO PROTEIN
DEGRADATION
The cellular traﬃcking network that takes place involves
movement of proteins from one intracellular compartment
to another. In some instances receptor proteins in late en-
dosome are deubiquitinated by chain-speciﬁc deubiquitinat-
ing enzymes at that site [73], while in others it appears that
proteins traﬃc to the proteasome for chain removal and are
then transported to the lysosome for degradation [74]. Se-
questosome 1/p62 has been shown to be a component of
the late endosomes [75, 76] ,a n di sa b l et os o r tp r o t e i n s ,
such as TrkA to the endosome [77]. Under stress conditions
late endosomes may fuse with autophagosomes [78], a pro-
cess that involves bulk phase sequestration of cytoplasmic
proteins. Aggregated proteins can be removed by the pro-
cess of autophagy [79], a process that is impaired in AD
[80]. Since the UPS may be impaired by protein aggregates
[34, 35], it is reasonable to propose that autophagy could
serve as a mechanism that cells hold in reserve for the re-
moval of protein aggregates. In this regard α-synuclein can
be degraded by both UPS and autophagy [81]. Therefore as
aggregates arise, cells could degrade these proteins by au-
tophagywhilepreservingthefunctionoftheUPS.Numerous
studies now indicate that cells may attempt to compensate
for impairments in one form of proteolysis (UPS) by dra-
matically elevating an alternate form of protein degradation
(autophagy) [82]. Recently,p62 has been shown to bind light
chain 3 (LC3), a protein that is tightly associated with the au-
tophagosomal membrane [83]. Under stress conditions p62
would thereby link polyubiquitinated aggregated proteins to
theautophagicmachinery,facilitatingtheirclearance.Indeed
this has been found to be the case for clearance of mutant
huntingtin [83]. Since p62 is localized to late endosomes
[75, 76], p62 through interaction with LC3 may be needed
in the recruitment of proteins for autophagy. Therefore de-
cline in p62 expression would not only lead to the accu-
mulation of polyubiquitinated proteins, but also to an ab-
sence of autophagosomes which in the appropriate genetic
environment may further contribute to an absence of in-
clusions and accumulation of misfolded proteins. Currently
we are studying whether neurons isolated from p62 −/−
mice fail to form autophagosomes and the eﬀects this may
have.
FUTURE DIRECTIONS FOR THERAPEUTIC TARGETS
Recent targets for therapy include reducing protein misfold-
ing and blocking aggregation. Strategies that promote degra-
dation of misfolded proteins, such as: (1) enhanced expres-
sion of chaperones; (2) overexpression of E3 ligases; (3) en-
hanced expression of shuttling proteins, such as p62; and
last, (4) up regulation of proteasome activity and/or au-
tophagy Since protein oxidation and aggregation are inti-
mately linked [64, 70], it is likely that more than one ap-
proach will be needed to eﬀectively remove aggregated pro-
teins and treat neurodegeneration. Clearly, early diagnostic
markersareneededtoeﬀectivelytimeinterventionandtreat-
ment.
CONCLUSIONS
Great strides have been made in the past ten years toward
understanding the pathological, cellular, biochemical, bio-
physical, and molecular bases of targeting proteins for degra-
dation. Two mechanisms have been studied which promote
the removal of aggregated/misfolded/polyubiquitinated pro-
teins: the UPS and autophagy. Both mechanisms are regu-
lated by p62. The observation that p62 plays an intimate
role in the regulation of protein signaling, polyubiquitina-
tion, and traﬃcking suggests that further study of its role as
a regulator of oxidative stress, neuropathology, and neuro-
toxicity in the brain is warranted. There is clearly a need to
learn more about p62 in the context of aging, genetic back-
ground,andenvironmentalfactors.Theconvergenceofthese
elements will determine the onset and severity of neurode-
generation. For AD, the greatest risk factor for the disease
is age. The known AD genes (PS1, PS2, APOE, APP) ac-
count for less than half the genetic variance in the disease,
suggesting there are many other risk determinant genes yet
to be identiﬁed. Altogether, these ﬁndings will contribute to
the development of more eﬀective means for treating AD
and for assessing those who might beneﬁt from therapeutic
intervention.10 Journal of Biomedicine and Biotechnology
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